Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores

Background. Invasive percutaneous liver parenchymal biopsy is the best test used to evaluate liver stiffness and fibrosis in the follow-up and treatment of chronic hepatitis B (CHB) patients. In this study, we aimed to indirectly evaluate the severity of liver parenchymal fibrosis with tests used in...

Full description

Saved in:
Bibliographic Details
Main Authors: Aysun Yakut, Murat Aladag
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:International Journal of Clinical Practice
Online Access:http://dx.doi.org/10.1155/2024/5540648
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832546148312678400
author Aysun Yakut
Murat Aladag
author_facet Aysun Yakut
Murat Aladag
author_sort Aysun Yakut
collection DOAJ
description Background. Invasive percutaneous liver parenchymal biopsy is the best test used to evaluate liver stiffness and fibrosis in the follow-up and treatment of chronic hepatitis B (CHB) patients. In this study, we aimed to indirectly evaluate the severity of liver parenchymal fibrosis with tests used in the laboratory. Methods. This retrospective study was conducted with 201 patients diagnosed with CHB who underwent liver biopsy between 2021 and 2022. Preprocedural examination information, laboratory tests, and histopathological data of the patients were taken from the hospital database and examined. “Aspartate aminotransferase (AST)-platelet ratio index” (APRI), “4 factor-based fibrosis index” (FIB-4) score, and “5 factor-based fibrosis index” (FIB-5) score were calculated and compared with liver histopathological features. Results. Of the 201 CHB patients, 76 were females and 125 were males. The average age of the patients was 38.05 ± 12.63 years. A weak, statistically significant correlation was observed between FIB-4 and APRI scores. The patients’ significant fibrosis scores were 31.3% and 33.8%, respectively (r = 0.313; r = 0.338; p=0.001; p<0.01). The very weak negative correlation of 17.4% between the patients’ FIB-5 score and fibrosis score was statistically significant (r = −0.174; p=0.014; p<0.05). Conclusions. According to the data we obtained in our study, while the APRI score and FIB-4 score can be used safely, more comprehensive studies are needed for the reliability of the FIB-5 score.
format Article
id doaj-art-9b3279fbc58841fa82439b421b01345c
institution Kabale University
issn 1742-1241
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series International Journal of Clinical Practice
spelling doaj-art-9b3279fbc58841fa82439b421b01345c2025-02-03T07:23:46ZengWileyInternational Journal of Clinical Practice1742-12412024-01-01202410.1155/2024/5540648Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 ScoresAysun Yakut0Murat Aladag1Department of GastroenterologyDepartment of GastroenterohepatologyBackground. Invasive percutaneous liver parenchymal biopsy is the best test used to evaluate liver stiffness and fibrosis in the follow-up and treatment of chronic hepatitis B (CHB) patients. In this study, we aimed to indirectly evaluate the severity of liver parenchymal fibrosis with tests used in the laboratory. Methods. This retrospective study was conducted with 201 patients diagnosed with CHB who underwent liver biopsy between 2021 and 2022. Preprocedural examination information, laboratory tests, and histopathological data of the patients were taken from the hospital database and examined. “Aspartate aminotransferase (AST)-platelet ratio index” (APRI), “4 factor-based fibrosis index” (FIB-4) score, and “5 factor-based fibrosis index” (FIB-5) score were calculated and compared with liver histopathological features. Results. Of the 201 CHB patients, 76 were females and 125 were males. The average age of the patients was 38.05 ± 12.63 years. A weak, statistically significant correlation was observed between FIB-4 and APRI scores. The patients’ significant fibrosis scores were 31.3% and 33.8%, respectively (r = 0.313; r = 0.338; p=0.001; p<0.01). The very weak negative correlation of 17.4% between the patients’ FIB-5 score and fibrosis score was statistically significant (r = −0.174; p=0.014; p<0.05). Conclusions. According to the data we obtained in our study, while the APRI score and FIB-4 score can be used safely, more comprehensive studies are needed for the reliability of the FIB-5 score.http://dx.doi.org/10.1155/2024/5540648
spellingShingle Aysun Yakut
Murat Aladag
Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores
International Journal of Clinical Practice
title Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores
title_full Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores
title_fullStr Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores
title_full_unstemmed Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores
title_short Noninvasive Tests to Assess Liver Stiffness in Patients with Chronic Hepatitis B: APRI, FIB-4, and FIB-5 Scores
title_sort noninvasive tests to assess liver stiffness in patients with chronic hepatitis b apri fib 4 and fib 5 scores
url http://dx.doi.org/10.1155/2024/5540648
work_keys_str_mv AT aysunyakut noninvasiveteststoassessliverstiffnessinpatientswithchronichepatitisbaprifib4andfib5scores
AT murataladag noninvasiveteststoassessliverstiffnessinpatientswithchronichepatitisbaprifib4andfib5scores